Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753115 · ClinicalTrials.gov registry record · Phase 2
Ciprofloxacin BioThrax Co-Administration Study
A Phase 2 study, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT01753115 is a Phase 2 study that has completed, run by Emergent BioSolutions. The registered enrollment target is 154 participants.
The verdict
NCT01753115, a Phase 2 study, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to determine whether there is any effect on the antibiotic, ciprofloxacin when taken before and after administration of a 3-dose series of BioThrax® (Anthrax Vaccine Adsorbed or AVA). This study will be conducted in the United States (US) in 154 healthy male and female volunteer subjects ages 18 to 45. The duration of study participation for each subject will be approximately 76 days (approximately 2.5 months)
Interventions
- DRUG Ciprofloxacin
- BIOLOGICAL BioThrax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01753115
The ClinicalTrials.gov registry entry for NCT01753115 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ciprofloxacin is the first listed.
NCT01753115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01753115 about?
NCT01753115 is a clinical study titled "Ciprofloxacin BioThrax Co-Administration Study". The purpose of this clinical trial is to determine whether there is any effect on the antibiotic, ciprofloxacin when taken before and after administration of a 3-dose series of BioThrax® (Anthrax Vaccine Adsorbed or AVA). This study will be conducted in the United States (US) in 154 healthy male an...
What is the current status of trial NCT01753115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2012-12. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01753115?
The interventions under investigation include: Ciprofloxacin (DRUG), BioThrax (BIOLOGICAL).
Who is sponsoring clinical trial NCT01753115?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.